ContraVir Pharmaceuticals Inc Stock Nasdaq
Equities
US21234W2026
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.22M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -76M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.12
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 15-12-31 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-02 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 13-05-14 |
Timothy Block
BRD | Director/Board Member | 69 | 13-11-25 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 22-06-26 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |